Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Lyell Immunopharma (LYEL) EBIT Margin (2020 - 2025)

Lyell Immunopharma's EBIT Margin history spans 5 years, with the latest figure at 248353.33% for Q3 2025.

  • For Q3 2025, EBIT Margin fell 9980922.0% year-over-year to 248353.33%; the TTM value through Sep 2025 reached 836358.54%, down 49172997.0%, while the annual FY2024 figure was 588122.95%, 39811680.0% down from the prior year.
  • EBIT Margin for Q3 2025 was 248353.33% at Lyell Immunopharma, up from 589250.0% in the prior quarter.
  • Across five years, EBIT Margin topped out at 30.55% in Q4 2022 and bottomed at 2214566.67% in Q3 2022.
  • The 5-year median for EBIT Margin is 236156.0% (2023), against an average of 481716.77%.
  • The largest annual shift saw EBIT Margin tumbled -221278224bps in 2022 before it skyrocketed 197841067bps in 2023.
  • A 5-year view of EBIT Margin shows it stood at 1684.55% in 2021, then soared by 98bps to 30.55% in 2022, then tumbled by -1498065bps to 457753.85% in 2023, then tumbled by -299bps to 1828609.09% in 2024, then skyrocketed by 86bps to 248353.33% in 2025.
  • Per Business Quant, the three most recent readings for LYEL's EBIT Margin are 248353.33% (Q3 2025), 589250.0% (Q2 2025), and 819528.57% (Q1 2025).